ghk-cu cas number ghk-cu cas GHK-CU - CAS

Rona Therapeutics advances INHBE siRNA into phase 1 clinical development

Last reviewed: November 16, 2025 Last reviewed: November 16, 2025 Comirnaty (Pfizer-BioNTech) mRNA COVID-19 vaccine is FDA-licensed for use in ages 5 years through 64 years with at least one underlying condition that puts them at risk for severe COVID-19 infection and individuals 65 years and older mNexspike (Moderna) is FDA-licensed for use in ages 12 through 64 years with at least one underlying condition that puts them at risk for severe COVID-19 infection and individuals 65 years and older Nuvaxovid (Sanofi-Novavax) is FDA-licensed for use in ages 12 through 64 years with at least one underlying condition that puts them at risk for severe COVID-19 infection and individuals 65 years and older Spikevax (Moderna) mRNA COVID-19 vaccine is FDA-licensed for use in ages 6 months through 64 years with at least one underlying condition that puts them at risk for severe COVID-19 infection and individuals 65 years and older Although the FDA licenses are limited in the age group younger than 65 years to those with underlying conditions that put them at risk for severe COVID-19 infection, the ACIP has recommended use based on individual decision-making (i.e., shared clinical decision-making) for all people age 6 months and older

Benefits: Gradual, natural tan without excess UV exposure May enhance sexual wellness and mood Supports skin protection from UV damage *Not FDA-approved for tanning

Solvent : Use deoxygenated solvents for reconstitution